|1.||Schlesinger, Naomi: 7 articles (02/2014 - 10/2010)|
|2.||Chakraborty, Abhijit: 5 articles (09/2015 - 01/2011)|
|3.||So, Alexander: 5 articles (03/2015 - 10/2010)|
|4.||Kuemmerle-Deschner, Jasmin B: 5 articles (12/2013 - 06/2009)|
|5.||Martini, Alberto: 4 articles (01/2016 - 02/2012)|
|6.||Lheritier, Karine: 4 articles (01/2016 - 01/2011)|
|7.||Yokota, Shumpei: 4 articles (01/2015 - 01/2012)|
|8.||Skerjanec, Andrej: 4 articles (11/2014 - 11/2013)|
|9.||Thuren, Tom: 4 articles (11/2014 - 10/2011)|
|10.||Krammer, Gerhard: 4 articles (12/2013 - 01/2011)|
|1.||Cryopyrin-Associated Periodic Syndromes
01/01/2011 - "Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study."
01/01/2011 - "Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?"
03/01/2013 - "Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results)."
12/01/2011 - "Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes."
09/01/2015 - "To study efficacy and safety of escalating doses of canakinumab, a fully human anti-IL-1β monoclonal antibody in the severe cryopyrin-associated periodic syndrome, neonatal-onset multisystem inflammatory disease (NOMID). "
11/01/2012 - "Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions."
10/01/2010 - "Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study."
12/01/2013 - "Total IL-1β kinetics and canakinumab pharmacokinetics were characterized by a population-based pharmacokinetic-binding model, where the estimated apparent in vivo dissociation constant (signifying binding affinity of canakinumab to circulating IL-1β) was 0.99 nmol/L in gouty arthritis patients. "
12/01/2013 - "Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis."
08/01/2013 - "Canakinumab (Ilaris®), an anti-interleukin-1β monoclonal antibody, is a novel approach to treat acute gouty arthritis flares in a targeted population of patients in whom treatment options are limited. "
07/01/2014 - "There are no clinical trials of canakinumab in patients with gout attacks refractory to several prior treatments. "
07/01/2014 - "Canakinumab for gout attacks. "
03/01/2014 - "Canakinumab for gout: a specific, patient-profiled indication."
09/01/2012 - "Canakinumab in gout."
07/01/2012 - "Crystal arthritis: Canakinumab relieves gout flares when treatment options are limited."
|4.||Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)
11/01/2010 - "Canakinumab was recently granted EU orphan drug status for systemic-onset juvenile idiopathic arthritis, and early clinical trials have established that administration of canakinumab every 2 weeks is both safe and effective. "
02/01/2012 - "A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features."
02/01/2012 - "To assess dosing, preliminary safety, and efficacy of canakinumab, a fully human anti-interleukin-1β (anti-IL-1β) antibody, in children with systemic juvenile idiopathic arthritis (JIA) and active systemic features. "
12/20/2012 - "Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis."
12/01/2015 - "A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis."
01/01/2014 - "Doses of canakinumab were varied (10 to 150 mg), but most people (255/368) were treated with canakinumab 150 mg. None of the studies provided data on participant-reported pain relief of 30% or greater. "
01/01/2011 - "SF-36 scores for physical functioning and bodily pain for the canakinumab 150 mg group approached those for the US general population by seven days post-dose and reached norm values by eight weeks post-dose. "
02/01/2014 - "Canakinumab has been shown to be efficacious in both reducing pain and inflammation in acute attacks, and for reducing the risk of recurrent attacks. "
07/30/2011 - "Canakinumab, a fully human anti-IL-1β monoclonal antibody, has been shown to produce rapid and sustained pain relief from acute flares in patients with difficult-to-treat disease, and both rilonacept and canakinumab have been shown to reduce the risk of recurrent flares. "
01/01/2014 - " pain (0- to 100-mm visual analogue scale (VAS), where 0 mm was no pain) was 36 mm after triamcinolone acetonide treatment; pain was further reduced by a mean of 11 mm with canakinumab treatment (mean difference (MD) -10.6 mm, 95% confidence interval (CI) -15.2 to -5.9). "
|3.||Interleukin 1 Receptor Antagonist Protein (Anakinra)
|4.||Triamcinolone Acetonide (Azmacort)
|5.||Interleukin-1 (Interleukin 1)
|6.||Uric Acid (Urate)
|10.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)